Case Study

Zydis® ODT Unlocks A Patient Preference For Rapid Onset In The Treatment Of Migraine

Source: Catalent

It has been reported that surveys of migraine patients have revealed a preference for oral medications with a rapid onset of action that leads to a resolution of their symptoms. Due to the random nature of migraine attacks, a dosage form that can be easily administered on the go without water can be beneficial for acute treatment of migraines.

Examine the case study on how Biohaven partnered with Catalent to formulate an orally disintegrating tablet (ODT) to create a convenient dosage form with a shorter Tmax for the treatment of acute migraine.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online